Dr. Sara Hurvitz explores if 4 cycles of T-DXd are sufficient in the neoadjuvant setting for HER2+ early breast cancer, highlighting insights from WSG-ADAPT HER2+/HR- and CompassHER2 trials.
5:34
0
